Wells Fargo raised the firm’s price target on C4 Therapeutics to $8 from $7 and keeps an Equal Weight rating on the shares following quarterly results. The firm notes the update gets it a bit more confident in cemi plus dex’s safety profile as it continues to dose escalate in the Phase 1/2 MM arm. Timelines were reiterated for updated data in the second half of 2024, Wells adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CCCC:
- C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
- C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum
- C4 Therapeutics presents new data for CFT1946 at AACR
- C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024